These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 9472648)

  • 1. A patient with minimal myeloma treatment who survived for 20 years.
    Behsen AD; Vandsemb EN; Slørdahl TS; Hjorth-Hansen H; Quist-Paulsen P; Misund K; Sponaas AM; Waage A
    Haematologica; 2024 Apr; 109(4):1301-1305. PubMed ID: 37794808
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical characteristics and prognosis of 56 multiple myeloma patients over 70 years of age complicated with other systemic diseases].
    Zhang H; Deng Q; Li JY; Zhao MF; Li YM
    Zhonghua Xue Ye Xue Za Zhi; 2018 Oct; 39(10):866-869. PubMed ID: 30369211
    [No Abstract]   [Full Text] [Related]  

  • 3. Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison.
    Khadka S; Balaji S; Kaur J; Solanki D; Kasianchyk M; Chowdhury H; Patel I; Qasim M; Desai M; Maiyani P; Moradiya DV; Lal D; Patel AA; Lekkala M
    Cureus; 2023 Oct; 15(10):e47319. PubMed ID: 38022254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
    Solmaz Medeni Ş; Türkyılmaz D; Acar C; Sevindik ÖG; Yüksel F; Pişkin Ö; Özcan MA; Demirkan F; Ündar B; Alacacıoğlu İ; Özsan GH
    Turk J Haematol; 2018 Nov; 35(4):271-276. PubMed ID: 29923493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic classification of death causes in multiple myeloma.
    Mai EK; Haas EM; Lücke S; Löpprich M; Kunz C; Pritsch M; Knaup-Gregori P; Raab MS; Schlenzka J; Bertsch U; Hillengass J; Goldschmidt H
    Blood Cancer J; 2018 Mar; 8(3):30. PubMed ID: 29520024
    [No Abstract]   [Full Text] [Related]  

  • 6. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma.
    Riccardi A; Mora O; Brugnatelli S; Tinelli C; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Bergonzi C; Giordano M; Delfini C; Nicoletti G; Rinaldi E; Piccinini L; Valentini D; Ascari E
    Br J Cancer; 1998; 77(3):485-91. PubMed ID: 9472648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol.
    Riccardi A; Mora O; Tinelli C; Porta C; Danova M; Brugnatelli S; Grasso D; Tolcà B; Spanedda R; De Paoli A; Barbarano L; Cavanna L; Giordano M; Delfini C; Nicoletti G; Bergonzi C; Rinaldi E; Piccinini L; Ascari E
    Eur J Cancer; 2003 Jan; 39(1):31-7. PubMed ID: 12504655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.
    Riccardi A; Mora O; Tinelli C; Valentini D; Brugnatelli S; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Giordano M; Delfini C; Nicoletti G; Bergonzi C; Rinaldi E; Piccinini L; Ascari E
    Br J Cancer; 2000 Apr; 82(7):1254-60. PubMed ID: 10755397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
    Bladé J; San Miguel JF; Fontanillas M; Alcalá A; Maldonado J; García-Conde J; Conde E; Conzález-Brito G; Moro MJ; Escudero ML; Trujillo J; Pascual A; Rozman C; Estapé J; Montserrat E
    J Clin Oncol; 1996 Jul; 14(7):2167-73. PubMed ID: 8683251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy in multiple myeloma.
    Oivanen TM; Palva IP
    N Engl J Med; 1996 Dec; 335(24):1844-5; author reply 1845. PubMed ID: 8965896
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.